BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
5/8 — Partial
Priority Review
POTELIGEO (mogamulizumab-kpkc) by Inpharmus is chemokine receptor type 4 interactions [moa]. Approved for chemokine receptor type 4 interaction [epc]. First approved in 2018.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POTELIGEO (mogamulizumab-kpkc) is a monoclonal antibody that targets chemokine receptor type 4 (CCR4), a protein expressed on certain T-cell lymphomas. It is administered via injection and works by blocking CCR4 interactions to eliminate malignant cells. The drug is indicated for patients with CCR4-positive cutaneous T-cell lymphomas and other hematologic malignancies.
$0.002BPart D
PeakProduct is at peak lifecycle with modest Medicare spending, indicating stable but niche market positioning with smaller commercial team requirements.
Mechanism of Action
Chemokine Receptor Type 4 Interactions
Pharmacologic Class:
Chemokine Receptor Type 4 Interaction
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Started Oct 2024
22 enrolled
T Cell LymphomaT-cell Lymphoma
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Started May 2023
10 enrolled
Cutaneous T Cell LymphomaMycosis Fungoides
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
Started Aug 2021
34 enrolled
Cutaneous T-Cell Lymphoma, RelapsedCutaneous T-Cell Lymphoma Refractory
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Started Sep 2019
150 enrolled
Leukemia/LymphomaCutaneous T Cell LymphomaATLL
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Started Aug 2016
36 enrolled
Solid TumorCancerCarcinoma
Worked on POTELIGEO at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.